Apollomics, Inc. APLMW

Full chart Compare

Set alert

0.01 USD 0.00 (+0.00%)

Nov 5, 2026, 3:55 PM EST

0.0102 Day range 0.012

0.012 52-week range 0.012

YTD: 0.00%
1 year: 0.00%

News

3 months ago globenewswire.com Apollomics Announces $10 Million Private Placement Transaction FOSTER CITY, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
4 months ago globenewswire.com Apollomics Regains Full Compliance with Nasdaq Listing Requirements FOSTER CITY, Calif., July 13, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
4 months ago globenewswire.com Apollomics Receives Nasdaq Deficiency Notice Regarding Minimum Market Value Requirement and Updates Rights for Vebreltinib (APL-101) in Asia FOSTER CITY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
6 months ago globenewswire.com Apollomics Reports Full Year 2025 Financial Results and Provides Clinical Updates and Business Progress Phase 2 studies ongoing to advance global development of vebreltinib, a highly potent, de-risked and differentiated c-MET Inhibitor with best-in-class and first-in-class potential. To date, more than…
7 months ago globenewswire.com Apollomics Inc. Announces $2.0 Million Bridge Financing FOSTER CITY, Calif., April 01, 2026 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced that it has entered into a $2.0 million unsecured Convertible…
10 months ago globenewswire.com Apollomics Reports First Half 2025 Financial Results FOSTER CITY, Calif., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM ) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
11 months ago globenewswire.com Apollomics Announces Settlement of Cayman Litigation FOSTER CITY, Calif., Nov. 19, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (“Apollomics” or the “Company”) (Nasdaq: APLM) announced today entering into a settlement agreement (the “Settlement Agreement”…
11 months ago globenewswire.com Apollomics Announces Changes to its Board of Directors and Composition of Committees FOSTER CITY, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California-based late-stage clinical biopharmaceutical company, today…
1 year ago globenewswire.com Apollomics Announces Continued Listing on The Nasdaq Stock Market Following Hearing Cancellation FOSTER CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a California based late-stage clinical biopharmaceutical company developing…
1 year ago globenewswire.com Nasdaq Resumes Trading in Apollomics Inc. NEW YORK, Oct. 14, 2025 (GLOBE NEWSWIRE) -- The Nasdaq Stock Market® (Nasdaq: NDAQ) announced that trading will resume in Apollomics Inc. Class A ordinary shares (Nasdaq: APLM) and warrants (Nasdaq:…
1 year ago globenewswire.com Apollomics, Inc. Company Operational Continuity Update FOSTER CITY, Calif., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), today announced the following company operational update.
1 year ago globenewswire.com Apollomics Reports Full Year 2024 Financial Results and Highlights Clinical Updates and Business Progress FOSTER CITY, Calif., April 03, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to…
1 year ago globenewswire.com Apollomics and LaunXP Announce Development and Commercialization Agreement for Vebreltinib FOSTER CITY, Calif. and TAIPEI, Taiwan, March 31, 2025 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics”), a late-stage clinical biopharmaceutical company developing multiple oncology…
1 year ago globenewswire.com Apollomics Announces Top-line Results for Phase 3 Bridging Trial of Uproleselan in China in Patients with Relapsed or Refractory Acute Myeloid Leukemia FOSTER CITY, Calif., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
1 year ago globenewswire.com Apollomics Regains Compliance with Nasdaq's Minimum Bid Price Requirement FOSTER CITY, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (the “Company”), a clinical-stage biopharmaceutical company developing medicines to address difficult-to-treat…
2 years ago globenewswire.com Apollomics to Present at the H.C. Wainwright 26th Annual Global Investment Conference FOSTER CITY, Calif., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com Apollomics Reports First Half 2024 Financial Results and Highlights Vebreltinib Clinical Progress FOSTER CITY, Calif., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com Apollomics Announces Positive Preliminary Data of Vebreltinib in Patients with Non-CNS MET Fusion Solid Tumors from its Phase 2 SPARTA Trial 43% overall response rate: Six confirmed responses (including one complete response in metastatic non-small cell lung cancer and five partial responses) confirmed by RECIST 1.1 out of 14 patients…
2 years ago globenewswire.com Apollomics Granted 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Requirement FOSTER CITY, Calif., July 16, 2024 (GLOBE NEWSWIRE) -- Apollomics Inc. (Nasdaq: APLM) (“Apollomics” or the “Company”), a late-stage clinical biopharmaceutical company developing multiple oncology…
2 years ago globenewswire.com Apollomics Announces Updated Strategic Focus and Leadership Team Changes Focus on vebreltinib study enrollment for non-small cell lung cancer (NSCLC) patients with Met Amplification mutations targets greatest unmet medical need Focus on vebreltinib study enrollment for…
3 years ago benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday's session, 406 companies made new 52-week lows.